SiliconBeat

OpenTable, the San Francisco-based developer of an electronic reservation booking system for restaurants, moved closer to pushing its proposed initial public offering out the door Tuesday when it estimated a price range of between $12 and $14 per-share price for the 3 million shares it plans to sell the public for the first time. At the high end, the offering would generate $42 million. About half of that would go to current shareholders selling some of their own stake in the IPO.

The pricing was part of a fourth amendment the company filed Tuesday to its original registration statement, which it updated with results for its quarter ended March 31. Sales for the quarter totaled Read the rest of this entry »

ArcSight, the lone Silicon Valley company to hold an initial public offering last year, said that Chairman and former chief executive Robert Shaw resigned Monday due to a “serious health condition” that was not further described. Read the rest of this entry »

It’s been a slow season for initial public offerings so whenever we see a new one registered, no matter where its located, we like to take a look. Today, Mayetok, a “development stage” company planning to market Ukrainian vacation properties”, registered its intention to offer 700,000 shares of itself to the public at 5 cents each.

Mayetok, founded in April (the 29th, to be exact, lest you were thinking its inception date might have been April 1), Read the rest of this entry »

This news won’t come as much of a surprise, but the number of initial public offerings worldwide fell in the third quarter by 82 percent from the year before to 20, while the total amount of cash invested fell 89 percent to $9.3 billion, according to a review by Renaissance Capital’s IPOhome.com.

And of the top 10 global IPOs, only one Read the rest of this entry »

Fluidigm, the South San Francisco biotech company that registered its initial public offering with the SEC back in April, is set to push it out to investors next week, according to Renaissance Capital. At least its investment banker underwriting the offering, Morgan Stanley, is still standing.

The company, which supplies what it calls integrated fluidic circuits — nanoscale devices that enable its life science customers to perform thousands of sophisticated biochemical measurements on samples smaller than the content of a single cell — is offering 5.3 million shares to the public for the first time. It has set a price range for the offering Read the rest of this entry »